The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer’s disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.
from Dementia Big http://ift.tt/2gWvWTs via alcoholic dementia
http://ift.tt/2his0Mz
No comments:
Post a Comment